FDA Releases Draft Guidance On CMC For Individualized ASO Therapies
A new FDA guidance released in Dec. 2021 acknowledges the difficulties inherent in manufacturing individualized antisense oligonucleotide (ASO)...
Source: pharmaceuticalonline.com
Stay updated with breaking news from Robert Simler. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
A new FDA guidance released in Dec. 2021 acknowledges the difficulties inherent in manufacturing individualized antisense oligonucleotide (ASO)...